ClinicalTrials.gg
CompletedNCT06704581Updated Oct 15, 2026

A Study of BGM0504 Injection in Participants With Obesity or Overweight

A Phase 3 interventional study of 5 mg BGM0504 injection and 10 mg BGM0504 injection administered subcutaneously (SC) once a week in Overweight or Obesity, sponsored by BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (part of BrightGene Bio-Medical Technology Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
652
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
Largest of 10
652 · median 78
Started
2024
with 2 others
Phase 3
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one has the largest enrollment, is one of 3 that started in 2024, is the only one in phase 3, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 652 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. as lead sponsor.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female aged 18 to 65 years inclusive at screening
  • ≥28 kg/m², or 24.0≤BMI\<28.0 kg/m² and previous diagnosis with at least one of the following comorbidities: i. Prediabetes (impaired fasting blood glucose and/or impaired glucose tolerance), hypertension, nonalcoholic fatty liver disease, or one or more of these; ii. Joint pain with weight bearing; iii. Dyspnea caused by obesity or obstructive sleep apnea syndrome
  • Weight change \< 5.0% (chief complaint) after diet and exercise control for at least 12 weeks before screening
  • Female participants who are not pregnant or lactating. Female participants with and their partners should use highly effective, medically accepted , will not have pregnancy and fertility plan, and refrain from donating ovum until one month after the end of the study

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening
  • Has been treated with GLP-1 receptor agonists or similar drugs containing the same target, or drugs used for weight control in the three months prior to screening
  • Secondary disease or drug-induced obesity, including : elevated cortisol (e.g. Cushing's syndrome), obesity due to pituitary and hypothalamic damage, obesity due to diet drug reduction/discontinuation, etc.;
  • History of pancreatitis
  • Have the currently uncontrolled thyroid diseases with stable treatment dose and abnormal results of thyroid function test occurred at screening
  • Previous history of moderate or severe depression, or PHQ-9 score ≥15, or history of other serious mental illness, or Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
652 participants (actual)

Study arms

  • Experimental
    5 mg BGM0504 injection

    Drug: 5 mg BGM0504 injection

  • Experimental
    10 mg BGM0504 injection

    Drug: 10 mg BGM0504 injection administered subcutaneously (SC) once a week

  • Experimental
    15 mg BGM0504 injection

    Drug: 15 mg BGM0504 injection

  • Placebo comparator
    BGM0504 placebo

    Drug: BGM0504 placebo

Interventions

  • 5mg BGM0504 injection administered subcutaneously (SC) once a week.

  • Drug10 mg BGM0504 injection administered subcutaneously (SC) once a week

    10mg BGM0504 injection administered subcutaneously (SC) once a week.

  • 15mg BGM0504 injection administered subcutaneously (SC) once a week.

  • DrugBGM0504 placebo

    BGM0504 placebo administered SC once a week.

07

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Change from baseline in body weight after 36 weeks of treatment

    Time frame: Baseline,Week 36

  2. Percentage of Participants Who Achieve≥5% Body Weight Reduction

    Percentage of Participants Who Achieve≥5% Body Weight Reduction

    Time frame: Baseline,Week 36

Secondary outcomes

  1. Percent Change From Baseline in Body Weight

    Percent Change from Baseline in Body Weight after 52weeks of treatment

    Time frame: Baseline, Week 52

  2. Change From Baseline in Body Weight

    Change from baseline in body weight

    Time frame: Baseline, Week36 and 52

  3. Percentage of Participants Who Achieve≥5% Body Weight Reduction

    Percentage of Participants Who Achieve≥5% Body Weight Reduction

    Time frame: Baseline, Week 36 and 52

  4. Percentage of Participants Who Achieve≥10% Body Weight Reduction

    Percentage of Participants Who Achieve≥10% Body Weight Reduction

    Time frame: Baseline, Week 36 and 52

  5. Percentage of Participants Who Achieve≥15%Body Weight Reduction

    Percentage of Participants Who Achieve≥15%Body Weight Reduction

    Time frame: Baseline, Week 36 and 52

  6. Percentage of Participants Who Achieve≥20% Body Weight Reduction

    Percentage of Participants Who Achieve≥20% Body Weight Reduction.

    Time frame: Baseline, Week 36 and 52

  7. Change From Baseline in Waist Circumference

    Change From Baseline in Waist Circumference after 52weeks of treatment.

    Time frame: Baseline, Week 36 and 52

  8. Change From Baseline in Body Mass Index (BMI)

    Change From Baseline in Body Mass Index (BMI) after 52weeks of treatment

    Time frame: Baseline, Week 36 and 52

  9. Change From Baseline in Fasting Glucose

    Change From Baseline in Fasting Glucose after 52weeks of treatment

    Time frame: Baseline, Week 36 and 52

  10. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change From Baseline in Hemoglobin A1c (HbA1c) after 52weeks of treatment.

    Time frame: Baseline, Week 36 and 52

08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2026, 16 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 16 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Mar 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 26, 2024
StartActual
Oct 29, 2024
Primary completionActual
Mar 17, 2026was Nov 2025
CompletionActual
Mar 17, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Peking University People's Hospital · Beijing, China
Show 1 removed
  • Peking University People's Hospital · Beijing, China
Oct 15, 2026
Start date
Oct 28, 2024→Oct 29, 2024
Oct 15, 2026
Primary completion
Nov 27, 2025→Mar 17, 2026 (actual)
Oct 15, 2026
Study completion
Mar 27, 2026→Mar 17, 2026 (actual)
Oct 15, 2026
Enrollment
620 (estimated)→652 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Peking University People's Hospital · Beijing, China
    Show 1 removed
    • Peking University People's Hospital · Beijing, China
    Start date Oct 28, 2024→Oct 29, 2024
    Primary completion Nov 27, 2025→Mar 17, 2026 (now actual)
    Study completion Mar 27, 2026→Mar 17, 2026 (now actual)
    Enrollment 620 (estimated)→652 (actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06704581
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Oct 29, 2024
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion